Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Randomized Phase II Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where cisplatin-Based Treatment is Not an Option
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine DFMO
Study Type: Prevention
Phase: II
NCTID: NCT02679144
Principal Investigator:
Kevin Ginn
International Penile Advanced Cancer Trial International Rare Cancers Initiative study
Study Type: Treatment
Phase: III
NCTID: NCT02305654
Principal Investigator:
Elizabeth Wulff-Burchfield
Multi-Center Randomized Controlled Phase 2b Clinical Trial To Evaluate The Safety And Efficacy Of Tvi-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Compared To Standard Therapy As A Treatment For Newly Diagnosed O6 -Methylguanine Methyltransferase Negative MGMT Unmethylated Grade 4 Astrocytoma Glioblastoma Multiforme; GBM
Study Type: Treatment
Phase: II
NCTID: NCT05685004
Principal Investigator:
Tolga Tuncer
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib NSC 748727 in Newly Diagnosed or Previously Untreated Low-Grade Glioma LGG Not Associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 NF1
Study Type: Treatment
Phase: III
NCTID: NCT04166409
Principal Investigator:
Keith August
A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
A Safety Run-In And Phase II Study Evaluating The Efficacy, Safety, And Impact On The Tumor Microenvironment Of The Combination Of Tocilizumab, Atezolizumab, And Fractionated Stereotactic Radiotherapy In Recurrent Glioblastoma
Study Type: Treatment
Phase: II
NCTID: NCT04729959
Principal Investigator:
Tolga Tuncer
A Multicenter Study of 5-Aminolevulinic Acid 5-ALA to Enhance Visualization of Malignant Tumor in Patients with Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Study Type: Treatment
Phase: II
NCTID: NCT02724579
Principal Investigator:
Keith August